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Introduction 
Teledermatology is increasingly being used in 
modern day medicine to provide care and diagnose 
dermatologic conditions in such diverse settings as 
military combat zones, rural areas in the U.S., and 
many parts of the world with reduced access to 
healthcare [1-4]. To support the use of 
teledermatology, many studies have demonstrated a 
shortage of dermatologists with only 36 
dermatologists per one million people, an average 
36 calendar day wait time for new patient 
appointments, and 49% of practicing dermatologists 
feeling that they need more dermatologists in their 
communities [5, 6]. With the advent of 
teledermatology, we are now better equipped to 
address this shortage by increasing access to care as 
shown in one study, which used teledermatology to 
improve dermatologic access among Medicaid 
enrollees by at least 63.8% [7]. Currently, 
teledermatology is commonly employed through an 
asynchronous modality with store-and-forward 
technology, whereby clinical images are obtained 
and sent to the dermatologist who can review the 
images and clinical history [1]. Advantages of 
teledermatology include cost reduction, 
improvement in triaging care, reduction in time to 
biopsy or excision, and reduction of in-person 
referrals by 72% [1, 8, 9]. At the University of 
Pittsburgh Medical Center, one study found that the 
use of teledermatology could reduce consultation to 
outpatient dermatology clinics by 65% [1]. Accuracy 
has also been observed to be elevated with inter-
observer agreement rates between 
teledermatology-based and clinic-based evaluation 
ranging between 70 and 90% [1]. 
Specifically, studies that focus on teledermatology 
applications in acne treatment have found 
comparable therapeutic outcomes between teleder- 
Abstract 
The application of teledermatology for evaluating 
acne patients has yielded comparable therapeutic 
outcomes with traditional face-to-face evaluation, 
but follow-up compliance between these modalities 
is not well-studied. Our objective is to compare the 
rate and duration of follow-up between acne 
patients initially evaluated by teledermatology 
versus in-person outpatient consultation. Electronic 
medical review of acne patients, 18-35 years-old seen 
via teledermatology and face-to-face evaluation at 
the University of Pittsburgh Medical Center between 
2010-2018 was performed. Teledermatology patients 
were less likely to follow-up in the first 90 days (13.0% 
versus 31.0%, P<0.001) compared to patients seen 
face-to-face with overall follow-up rates of 22% 
among both modalities. The median time to follow-
up was 45.5 days (IQR: 13/57) in the teledermatology 
group compared to 64 days (IQR: 56/77) in the face-
to-face group (P<0.001). Teledermatology patients 
were more likely to be treated with oral antibiotics 
(43.0% versus 28.5%) or oral spironolactone (18.5% 
versus 12.5%) compared to patients seen face-to-face 
(P<0.001). Teledermatology poses a promising 
solution to extend dermatologic care with earlier 
access to follow-up. Our data demonstrates a need to 
improve teledermatology follow-up education to 
improve follow-up care. 
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matology consultation and outpatient consultation 
with fewer adverse reactions; furthermore, patients 
seen in a teledermatology setting were satisfied with 
mobile services and none requested further in-
person consultation [10]. Another study comparing 
outcomes at four follow-up e-visits versus 
conventional office care demonstrated a similar 
decrease in total inflammatory lesion count along 
with comparable subject and dermatologist 
satisfaction with e-visit versus standard in-office 
evaluation [11]. However, follow-up after initial 
teledermatology evaluation for acne has not been 
compared to that of outpatient dermatology. This is 
an important part of establishing care after 
consultation and is even listed in the American 
Telemedicine Association Practice Guidelines for 
Teledermatology issued in 2016 [12]. To the author’s 
knowledge, no articles have been published on this 
topic to date. The objective of this study was to 
analyze whether acne patients seen via 
teledermatology had different follow-up rates 
compared to those of outpatient, face-to-face 
dermatology visits within three months of the initial 
visit. 
 
Methods 
Study design 
This retrospective chart review was approved by the 
institutional review board of University of Pittsburgh 
(STUDY18120157) and compares follow-up 
compliance in teledermatology with that of face-to-
face outpatient dermatology visits at an urban 
tertiary care center, UPMC, from 2010 to 2018. A list 
of eligible patient charts was generated using the 
UPMC Health Record Research Request service, and 
inclusion criteria consisted of patients aged 18-35 
newly diagnosed with an ICD 9 (706.1) or 10 code 
(L70.0) of acne vulgaris through teledermatology or 
face-to-face visits. Patients currently receiving or 
requiring oral isotretinoin therapy were excluded. 
We first identified and reviewed 200 eligible patient 
charts seen via teledermatology and then selected 
200 patients seen through face-to-face meetings, 
who matched the age and gender distribution in the 
teledermatology group. Electronic medical records 
were reviewed for gender, ethnicity, age of first visit, 
date of first visit, date of first follow-up visit, follow-
up modality (teledermatology or face to face), acne 
type or severity, insurance status, and treatment 
type. Our primary outcome was defined as follow-up 
within three months of their initial visit as suggested 
by American Academy of Dermatology guidelines to 
minimize bacterial resistance [13]. Treatment was 
divided into four groups regardless of oral 
contraceptive (OCP) treatment: only topical therapy, 
oral antibiotics with or without topical therapy, oral 
spironolactone with or without topical therapies, 
and oral antibiotics and spironolactone with or 
without topical therapy. Of note, any patient without 
a recorded insurance provider in the electronic chart 
was documented as uninsured. 
Table 1. Teledermatology versus face-to-face acne evaluation demographics. 
 eDermatology (200) Face-to-Face Visit (200) Both (400) 
Sex 
Male (%) 35 17.5% 35 17.5% 70 17.5% 
Female (%) 165 82.5% 165 82.5% 330 82.5% 
Age at Diagnosis 
Mean (SD) 25.7 ±4.1 25.7 ±4.1 25.7 ±4.1 
Ethnicity 
White (%) 152 76.0% 170 85.0% 322 80.5% 
Black or African American (%) 17 8.5% 6 3.0% 23 5.8% 
Hispanic/Latino (%) 1 0.5% 3 1.5% 4 1.0% 
Asian (%) 13 6.5% 15 7.5% 28 7.0% 
Native American (%) 0 0.0% 1 0.5% 1 0.3% 
Not available/declined (%) 17 8.5% 5 2.5% 22 5.5% 
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Statistical analysis 
The primary analysis in this study focused on 
whether patients initially seen by teledermatology or 
face-to-face visit had follow-up within three months 
of their initial visit. Descriptive statistics were 
presented as mean and standard deviation or 
median with inter-quartile range for continuous 
variables; frequency with percent was used to 
describe categorical variables. Differences in patient 
characteristics between teledermatology and face-
to-face visits were assessed using Pearson Chi-
square tests for categorical variables and t-tests or 
Wilcoxon rank sum tests for continuous variables.  
Results with P<0.05 were considered statistically 
significant. All analyses were performed using Stata, 
version 15 (StataCorp. College Station, TX: StataCorp 
LLC).  
 
Results 
Demographics and acne type 
In this study, 400 cases were evaluated including 200 
teledermatology cases with initial visits between July 
2015 and October 2018 and 200 face-to-face cases 
with initial visits between November 2010 and  
Table 2. Teledermatology versus face-to-face acne evaluation clinical characteristics. 
 
eDermatology 
(200)
Face-to-Face Visit 
(200) Both (400) P value
Acne type* 
Comedonal acne (%) 10 5.0% 46 23.0% 56 14.0%  
Inflammatory acne (%) 28 14.0% 64 32.0% 92 23.0%  
Hormonal acne (%) 30 15.0% 33 16.5% 63 15.8%  
Nodulocystic (%) 9 4.5% 10 5.0% 19 4.8%  
Scarring acne (%) 0 0.0% 7 3.5% 7 1.8%  
Steroid acne (%) 0 0.0% 2 1.0% 2 0.5%  
Acne nos (%) 138 69.0% 99 49.5% 237 59.3%  
Treatment modality <0.001 
Only topical treatment with or without ocp (%) 62 31.0% 106 53.0% 168 42.0%  
Oral antibiotics with or without topicals or ocp (%) 86 43.0% 57 28.5% 143 35.8%  
Oral spironolactone with or without topicals or 
ocp (%) 37 18.5% 25 12.5% 62 15.5%  
Both antibiotic and spironolactone treatment 
with or without topicals or ocp (%) 
15 7.5% 12 6.0% 27 6.8%  
 
Median overall days to follow-up (p25/p75) 139 66, 342 92 70, 158 98 68, 213  
Number of patients that followed-up in 90 days 
(%) 26 13.0% 62 31.0% 88 22.0% <0.001 
Median days to follow-up among patients 
returning in 90 days (p25/75) 
45.5  13, 57  64 56, 77  61.5 45.5, 
75.5 
<0.001 
Modality of follow-up+ 
eDermatology follow-up 8 30.8% 0 0.0% 8 9.1%  
Face-to-face visit follow-up 18 69.2% 62 100% 80 90.9%  
Insurance status 0.8 
Patients without documented insurance status 
(%) 33 16.5% 35 17.5% 68 17.0%  
Patients with documented insurance status (%) 167 83.5% 165 82.5% 332 83.0%  
 
*Patients may fall into more than one acne type based on chart review. 
+Follow-up percentages were calculated based on a total of 32 eDermatology and 63 face-to-face patients having follow-up. 
Abbreviations: OCP: Oral contraceptive; Acne not otherwise specified: Acne NOS 
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October 2018. Although we attempted to match on 
one-year age stratum, there were slightly more 26-
year-old males among the teledermatology cases 
who could not be perfectly matched in the face-to-
face case group. Demographic characteristics for 
teledermatology, face-to-face, and overall visits are 
described in Table 1. A description of acne type 
among teledermatology and face-to-face initial visits 
is shown in Table 2. Notably, some patients were 
documented as having more than one type of acne. 
In our cohort of patients, 59.3% (237/400) of patients 
were diagnosed as acne not otherwise specified 
(Acne NOS), including 69.0% (138/200) and 49.5% 
(99/200) of teledermatology and face-to-face 
patients, respectively (Table 2). 
Treatment modality and insurance type 
Recorded treatment modalities for teledermatology 
and face-to-face cases are also demonstrated in 
Table 2. The greatest percentage of 
teledermatology cases were treated with oral 
antibiotics with or without topical therapy or OCPs at 
43% (86/200). On the other hand, the highest 
percentage of face-to-face cases were treated with 
only topical therapy with or without OCPs at 53% 
(106/200). Importantly, antibiotics with concomitant 
spironolactone with or without topical therapy or 
OCPs represented the smallest percentage of cases 
in both teledermatology and face-to-face groups at 
7.5% (15/200) ad 6.0% (12/200), respectively. 
Differences in treatment modality were significant 
between the teledermatology and face-to-face cases 
(P<0.001). Only 5.8% (3/52) of teledermatology and 
2.7% (1/37) of face-to-face patients prescribed with 
spironolactone did not demonstrate oral 
contraception discussion. 
In Table 3, the 160 patients with at least one 
documented acne type were categorized as follows: 
only comedonal-type acne, inflammatory or 
hormonal acne patients with or without comedonal 
acne, and nodulocystic acne patients with or without 
comedonal, inflammatory, or homornal acne. All 
patients (13/13) with only comedonal-type acne 
were treated with topical therapy. Most 
inflammatory or hormonal acne patients with or 
without comedonal acne were treated with either 
topical agents at 33.6% (43/128) or oral antibiotics 
with or without topical agents at 39.06% (50/128). 
The majority of nodulocystic patients with or without 
comedonal, inflammatory, or hormonal acne were 
treated with oral antibiotics with or without topical 
agents (47.4%, 9/19) or both antibiotics and 
spironolactone with or without topical agents 
(21.1%, 4/19), demonstrating that treatment 
modality followed trends in recorded acne severity 
type. Treatment modality distribution was similar 
across specified versus unspecified acne types. 
In addition, the percentage of patients with 
documented insurance was 83.5% (167/200) of 
teledermatology patients and 82.5% (165/200) of 
face-to-face patients (Table 2), (P=0.8). No 
significant difference was noted between prescribed 
treatment modality and patient insurance status 
(P=0.8). 
Follow-up 
Median duration to follow-up was 45.5 days (IQR: 13, 
57) for teledermatology cases and 64 days (IQR: 56, 
77) for face-to-face cases (P<0.001), implying earlier 
access to care via electronic than in-person 
scheduling. Importantly, 13% (26/200) of 
teledermatology cases and 31% (62/200) of face-to-
Table 3. Acne treatment modality by acne type*. 
 
Comedonal 
Acne (13)
Inflammatory or 
Hormonal Acne 
(128) 
Nodulocystic 
Acne (19)
Only topical treatment with or without OCP (%) 13 100% 43 33.6% 3 15.8% 
Oral antibiotics with or without topicals or OCP (%) 0 0% 50 39.1% 9 47.4% 
Oral spironolactone with or without topicals or OCP (%) 0 0% 27 21.1% 3 15.8% 
Both antibiotic and spironolactone treatment with or without 
topicals or OCP (%) 0 0% 8 6.3% 4 21.1% 
 
*Patients were categorized by recorded acne type as follows: only comedonal-type acne, inflammatory or hormonal acne patients with or without 
comedonal acne, and nodulocystic acne patients with or without comedonal, inflammatory, or homornal acne.able. OCP, oral contraceptive. 
Volume 26 Number 4| April 2020| 
26(4):1 
 
 
- 5 - 
Dermatology Online Journal  ||  Original 
face cases followed-up within the standard 90-day 
interval (P<0.001). The overall follow-up rate for both 
modalities was only 22%; in addition, 8/26 (30.8%) 
teledermatology cases completed follow-up via 
teledermatology whereas 18/26 (69.2%) 
teledermatology cases completed follow-up via 
face-to-face. All face-to-face follow-ups (62/62) 
completed follow-up in-person (Table 2). Notably, 
no statistically significant differences in 90-day 
follow-up rates were noted based on gender (P=0.6), 
age (P=0.08), documented insurance status (P=0.2), 
or treatment modality (P=0.5). 
In the face-to-face group, 26 patients had initial 
evaluation prior to that of the teledermatology cases. 
These 26 patients were significantly younger than 
other face-to-face patients (P=0.009), but there were 
no significant differences in terms of gender, 
treatment modality, or follow-up rate (P>0.05). 
 
Discussion 
We found that patients seen via teledermatology 
have lower overall follow-up rates than those seen in 
a face-to-face setting (13 versus 31%, P<0.001). This 
result is consistent with patient and referring 
provider concerns of teledermatology with surveys 
demonstrating that 21% of patients and 26% of 
referring providers complained about 
inconsistencies in follow-ups. However, in our study, 
only 22% of the combined cohort had any follow-up, 
demonstrating room for improvement in both 
modalities [14]. Interestingly, teledermatology 
patients were also more likely to be treated with oral 
antibiotics with or without topical therapy or OCPs 
(43.0% versus 28.5%) or oral spironolactone with or 
without topical agents or OCPs (18.5% versus 12.5%). 
This can possibly indicate that acne patients seen via 
teledermatology are getting better control of their 
acne with stronger oral medications and are, 
therefore, less likely to follow-up. However, follow-
up rates did not differ based on treatment modality 
overall (P=0.5), suggesting that it was less likely to 
play a role. 
The greater percentage of patients treated with 
spironolactone or oral antibiotics among 
teledermatology patients should also necessitate 
closer follow-up to ensure that patients are not 
encountering complications of their treatment. 
Interestingly, our data showed that only 5.8% of 
teledermatology and 2.7% of face-to-face patients 
prescribed spironolactone did not document oral 
contraception discussion. This demonstrates that a 
majority of spironolactone cases mentioned OCP 
discussion among both teledermatology and face-
to-face visits; the remaining cases may relate to lack 
of documentation, demonstrating the importance of 
documenting oral contraception with 
spironolactone if discussed. According to one 
review, although an effective medication for acne 
with demonstrated improvement in facial acne by 
73.1%, spironolactone has been associated with such 
side effects as menstrual irregularities and 
lightheadedness in 46% of treated patients with 5% 
discontinuing the medication secondary to side 
effects [15]. Other notable documented adverse 
effects include diuresis, breast tenderness or 
enlargement, fatigue, hyperkalemia, headache, and 
teratogenicity [13,16]. The association of chronic oral 
tetracycline antibiotic use with increased risk of 
antibiotic resistance, upper respiratory tract 
infections, inflammatory bowel disease, pharyngitis, 
C. difficile infection, and Candida vulvovaginitis has 
been demonstrated [13, 17, 18]. In fact, owing to the 
risk of developing bacterial resistance, the American 
Academy of Dermatology guidelines currently 
recommend re-evaluation of systemic antibiotic use 
every 3-4 months [13]. This level of follow-up not 
only allows for monitoring for potential adverse 
effects, but it also allows for adjustment of therapy as 
well as assessment of compliance, response to 
treatment, patient satisfaction, and tolerability [19]. 
Furthermore, we do not notice a significant 
difference in the percentage of patients with 
documented insurance status among 
teledermatology and face-to-face patients seen for 
an initial diagnosis of acne. Thus, insurance status is 
unlikely to play a role in differences in the rate of 
follow-up between patients using teledermatology 
versus face-to-face visits. 
In addition, it is important to note that all face-to-
face visits completed follow-up in-person, and 30.8% 
(8/26) of teledermatology patients completed 
follow-up via teledermatology. This could relate to  
Volume 26 Number 4| April 2020| 
26(4):1 
 
 
- 6 - 
Dermatology Online Journal  ||  Original 
patient preference, teledermatologist recommendation, 
or a possible lack of patient education on the ability 
to follow-up via teledermatology. The fact that 
teledermatology patients in our study had shorter 
median follow-up times compared to face-to-face 
patients may also show easier access to care via this 
modality. Further information and education on the 
ability to have teledermatology follow-ups could 
potentially maximize effective treatment and 
prevention of complications. 
Study limitations include the retrospective nature of 
the study as it does not account for unmeasured 
confounders that could affect whether a patient 
chooses to use teledermatology, including the 
average distance from the treating provider. 
Furthermore, a significant percentage of patients, 
59% (236/400), did not have a specified type of acne 
or level of acne severity as recorded by the 
evaluating dermatologist. However, we were able to 
use prescribed treatment as an approximate 
surrogate for acne severity based on the 
demonstrated correlation between acne severity 
type and treatment modality. 
Conclusion 
In conclusion, this data demonstrates the increasing 
need to establish teledermatology follow-up 
education for acne to improve follow-up care for 
patients seen via this modality and make it 
comparable to that of in-person visits. However, our 
paper also demonstrates significantly shorter 
teledermatology follow-up times potentially 
indicating earlier access to care. Further information 
and education on the ability to have 
teledermatology follow-up could potentially 
maximize effective treatment and prevent 
complications. Future prospective studies can 
evaluate interventions to improve follow-up rates 
such as sending electronic follow-up reminders and 
limiting medication prescription duration to ensure 
follow-up compliance and to decrease risk for 
potential antibiotic resistance. 
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